Cenobamate is a tetrazole-derived antiseizure medication with a dual, complementary mechanism:
Its dual receptor profile was designed to deliver strong anti-seizure efficacy while enabling a tolerability-guided, individualized titration.
Cenobamate is indicated as adjunctive treatment of focal-onset seizures, with or without secondary generalization, in adult patients with epilepsy inadequately controlled despite treatment with at least two antiseizure medications.
| Week | Daily Dose |
|---|---|
| Weeks 1–2 | 12.5 mg |
| Weeks 3–4 | 25 mg |
| Weeks 5–6 | 50 mg |
| Weeks 7–8 | 100 mg |
| Weeks 9–10 | 150 mg |
| Week 11 onward | 200 mg (maintenance; max 400 mg/day) |
Dose adjustment or caution may be required in:
Refer to the local Prescribing Information for complete dosing recommendations.
Drug Reaction with Eosinophilia and Systemic Symptoms
Serious, potentially fatal hypersensitivity reactions have been reported, most commonly emerging within the first 6–8 weeks of treatment, though onset may occur later. Discontinue immediately and provide supportive care if DRESS is suspected.
Dose-dependent QT shortening has been observed — up to 66% of subjects showed QTc shortening >20 msec at supratherapeutic doses. Avoid use in patients with Familial Short QT Syndrome and use caution with other QT-shortening drugs.
As with other antiseizure medications, monitor patients for emergence or worsening of depression, suicidal thoughts, or unusual changes in mood or behavior, especially during treatment initiation and dose adjustments.
Dose-dependent somnolence/fatigue, dizziness and coordination disturbance, and cognitive dysfunction may occur, most often within the first 4 weeks of therapy. Advise patients against hazardous activities requiring mental alertness until effects are known.
Abrupt discontinuation increases the risk of rebound seizures and status epilepticus; taper gradually over at least 2 weeks unless safety concerns require faster withdrawal.
Frequently reported adverse events include:
Monitor systematically throughout titration and early therapy.
At baseline and during titration.
Signs of hypersensitivity: fever, rash, lymphadenopathy and organ involvement.
Monitor liver function during treatment.
Mood changes and suicidal ideation, particularly during early therapy.
Assess sedation, coordination, cognition and vision.
Evaluate clinical response and tolerability at each titration step.
CEBRIUS® (Cenobamate Tablets) — complete package insert
Cenobamate is a moderate CYP2B6 and CYP3A4/5 inducer, a weak CYP2C8 inducer, and a moderate-to-strong CYP2C19 inhibitor. Dose modification of concomitant medications may be necessary:
| Concomitant Medication Type | Specific Examples | Mandated Dosing Adjustment |
|---|---|---|
| CYP2C19 substrates (inhibited by cenobamate) | Clobazam (N-desmethylclobazam), phenytoin, phenobarbital | Reduce dose of concomitant medication and monitor closely; phenytoin dose reduction up to 50% may be needed |
| CYP3A4/5 substrates (induced by cenobamate) | Hormonal contraceptives, midazolam | May reduce substrate efficacy — use additional or alternative non-hormonal contraception |
| CYP2B6 substrates (induced by cenobamate) | Bupropion, efavirenz | May require dose increase of the concomitant substrate |
| Sodium-channel-blocking ASMs / high drug load | Carbamazepine, lamotrigine, phenytoin, clobazam | Proactively lower concomitant ASM dose during cenobamate titration, based on clinical judgment |
Healthcare professionals are encouraged to review the complete locally approved Prescribing Information for:
Cenobamate (Cebrius) is a dual-mechanism antiseizure medication indicated as adjunctive therapy for drug-resistant focal epilepsy, with demonstrated seizure-frequency reduction and seizure-freedom potential across the pivotal C013, C017 and C021 trials. Successful use depends on strict adherence to the slow titration schedule, proactive management of concomitant ASM drug load, and vigilant monitoring for DRESS, QT shortening, and neurological adverse effects. Clinical use should be guided by patient characteristics, treatment goals, tolerability considerations, and approved local prescribing information.